Stockreport

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Inc.  (NGNE) 
PDF Company to host webcast to review data on November 11 at 4:30 p.m. ETLate-breaker poster to be presented during Child Neurology Society Meeting on November 12 NEW YOR [Read more]